Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03153319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2025 to Jan 2027
    • Study completion date: Jun 2026 to Feb 2027
    v10
  2. Collaborators expanded, about 11 wordsv9
  3. Primary completion date: Dec 2022 to Dec 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Feb 2023 to Jun 2026
    • Site details revised
    v8
  4. Primary completion date: Jun 2022 to Dec 2022v7
  5. Primary completion date: Dec 2021 to Jun 2022v6 Show 5 more changesShow less
    • Study completion date: Oct 2022 to Feb 2023
    • Study site revised
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 2 words
    • Study title expanded, about 1 word
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Jun 2020 to Dec 2021
    • Study completion date: Jun 2020 to Oct 2022
    v5
  2. Site contact updatedv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2017 to Jun 5, 2017
    • Site details revised
    v3
  4. Secondary endpoints revised (4)
    • Study title shortened, about 3 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
Trial Details
NCT Number NCT03153319
Lead Sponsor Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions
(from sponsor)		 Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Related terms Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov